HUTCHMED Surges Over 3% in Intraday Trading as SACHI Phase III Study Results Published in The Lancet

Deep News01-15

HUTCHMED (00013) rose more than 3% during the trading session. At the time of writing, the stock was up 2.39%, trading at HKD 23.98, with a turnover of HKD 77.411 million.

According to an announcement on HUTCHMED's official WeChat account on January 14th, the company announced that the results of the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study evaluating the combination therapy of savolitinib (Orpathys®) and osimertinib (Tagrisso®) for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have experienced disease progression after first-line EGFR tyrosine kinase inhibitor therapy and have MET amplification.

Savolitinib is described as a potent, highly selective oral MET TKI, co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is an irreversible, third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195712170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 10:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195712170","market":"nz","top_or_hot":-1,"title":"HUTCHMED Surges Over 3% in Intraday Trading as SACHI Phase III Study Results Published in The Lancet","media":"Deep News","content":"<p>HUTCHMED (00013) rose more than 3% during the trading session. At the time of writing, the stock was up 2.39%, trading at HKD 23.98, with a turnover of HKD 77.411 million.</p>\n<p>According to an announcement on HUTCHMED's official WeChat account on January 14th, the company announced that the results of the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study evaluating the combination therapy of savolitinib (Orpathys®) and osimertinib (Tagrisso®) for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have experienced disease progression after first-line EGFR tyrosine kinase inhibitor therapy and have MET amplification.</p>\n<p>Savolitinib is described as a potent, highly selective oral MET TKI, co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is an irreversible, third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED Surges Over 3% in Intraday Trading as SACHI Phase III Study Results Published in The Lancet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED Surges Over 3% in Intraday Trading as SACHI Phase III Study Results Published in The Lancet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-15 10:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) rose more than 3% during the trading session. At the time of writing, the stock was up 2.39%, trading at HKD 23.98, with a turnover of HKD 77.411 million.</p>\n<p>According to an announcement on HUTCHMED's official WeChat account on January 14th, the company announced that the results of the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study evaluating the combination therapy of savolitinib (Orpathys®) and osimertinib (Tagrisso®) for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have experienced disease progression after first-line EGFR tyrosine kinase inhibitor therapy and have MET amplification.</p>\n<p>Savolitinib is described as a potent, highly selective oral MET TKI, co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is an irreversible, third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1195712170","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195712170","pubTimestamp":1768445662,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"HUTCHMED (00013) rose more than 3% during the trading session. At the time of writing, the stock was up 2.39%, trading at HKD 23.98, with a turnover of HKD 77.411 million. According to an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1191":"制药","BK4531":"中概回港概念","III":"信息服务","00013":"和黄医药","BK4134":"信息科技咨询与其它服务","BK1588":"回港中概股","BK1587":"次新股","BK4007":"制药","HCM":"和黄医药"},"translate_title":"SACHI III期研究结果发表在《柳叶刀》上，和黄医药盘中飙升逾3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"HCM":1,"00013":1},"content_text":"HUTCHMED (00013) rose more than 3% during the trading session. At the time of writing, the stock was up 2.39%, trading at HKD 23.98, with a turnover of HKD 77.411 million.\nAccording to an announcement on HUTCHMED's official WeChat account on January 14th, the company announced that the results of the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study evaluating the combination therapy of savolitinib (Orpathys®) and osimertinib (Tagrisso®) for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have experienced disease progression after first-line EGFR tyrosine kinase inhibitor therapy and have MET amplification.\nSavolitinib is described as a potent, highly selective oral MET TKI, co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is an irreversible, third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195712170","isCrawlerRequest":true}